GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Forward PE Ratio

China Isotope & Radiation (HKSE:01763) Forward PE Ratio : 0.00 (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Forward PE Ratio?

China Isotope & Radiation's Forward PE Ratio for today is 0.00.

China Isotope & Radiation's PE Ratio without NRI for today is 10.98.

China Isotope & Radiation's PE Ratio for today is 8.73.


China Isotope & Radiation Forward PE Ratio Historical Data

The historical data trend for China Isotope & Radiation's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Forward PE Ratio Chart

China Isotope & Radiation Annual Data
Trend
Forward PE Ratio

China Isotope & Radiation Semi-Annual Data
Forward PE Ratio

Competitive Comparison of China Isotope & Radiation's Forward PE Ratio

For the Medical Devices subindustry, China Isotope & Radiation's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Isotope & Radiation's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's Forward PE Ratio falls into.



China Isotope & Radiation Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


China Isotope & Radiation  (HKSE:01763) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


China Isotope & Radiation Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines